Purchase this article with an account.
Alexander Foss, Faruque Ghanchi, Jonathan Gibson, Lauren Scott, ; IOP changes in study and fellow eyes by treatment frequency in the IVAN clinical trial. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1647.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To describe changes in intraocular pressure in the “alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN) clinical trial which compared two drugs ranibizumab versus bevacizumab and two treatment regimens namely monthly or as needed (discontinuous).
We computed the mean IOP at each study visit and the difference in IOP between study and fellow eyes at baseline and the final treatment at month 23. IVAN participants received a median of 18 treatments. We dichotomized participants to those who received fewer than 19 or 19+ treatments. The IOP was also recorded post- injection of drug. The IOP spike after each treatment was calculated and compared between the two groups using a mixed regression model.
Of the 610 participants in the IVAN trial 525 were followed up for two years. The mean (SD) IOP at baseline in study and fellow eyes was similar; 15.33 (3.34) and 15.38 (3.49) respectively. At the month 23 visit the mean IOP in study and fellow eyes were 15.46 (3.37) and 15.33 (3.28) respectively. The mean post injection spike in IOP in the study eye was 3.19 (range -13 to +43) at the first visit and 3.96 (-18 to +21) at month 23. The post injection IOP spike was not significantly different when participants were dichotomized into two groups by the median number of treatments (p= 0.66) and did not change over time (p= 0.83).
Treatment with anti-VEGF agents did not result in elevation of the IOP during the two years of the IVAN clinical trial. Furthermore the post injection spikes in IOP were not influenced by the number of treatments.
This PDF is available to Subscribers Only